Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc.

Biotechnology • Healthcare • New Haven, CT, United States • TRVI (NGM)

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

203 304 2499 195 Church Street, New Haven, CT 06510, United States

Stock Performance (90 Days)

Data through Dec 30, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Trevi Therapeutics (TRVI) targets next phase of growth with leadership change - MSN
MSN • Dec 30
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer - PR Newswire
PR Newswire • Dec 4
WilmerHale Advises Trevi Therapeutics, Inc. in $115 Million Public Offering - WilmerHale
WilmerHale • Jun 9
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - PR Newswire
PR Newswire • Nov 13
How Trevi Therapeutics’ (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations - Yahoo Finance
Yahoo Finance • Nov 14

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Trevi Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Trevi Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Trevi Therapeutics, Inc. have?
Trevi Therapeutics, Inc. has approximately 34 employees.
What industry is Trevi Therapeutics, Inc. in?
Trevi Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Trevi Therapeutics, Inc. a publicly traded company?
Yes, Trevi Therapeutics, Inc. is publicly traded under the ticker symbol TRVI on the NGM. The company has a market capitalization of approximately $1.62 billion.
Where is Trevi Therapeutics, Inc. headquartered?
Trevi Therapeutics, Inc. is headquartered in New Haven, CT, United States at 195 Church Street, New Haven, CT 06510, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.